ABSTRACT
Hypercytokinemia, or cytokine storm, often complicates the treatment of viral and bacterial infections, including COVID-19, leading to the risk of thrombosis. However, the use of currently available direct anticoagulants for the treatment of COVID-19 patients is limited due to safety reasons. Therefore, the development of new anticoagulants remains an urgent task for organic and medicinal chemistry. At the same time, new drugs that combine anticoagulant properties with antiviral or antidiabetic activity could be helpfull in the treatment of COVID-19 patients, especially those suffering from such concomitant diseases as arterial hypertension or diabetes. We have synthesized a number of novel substituted azoloazines, some of which have previously been identified as compounds with pronounced antiviral, antibacterial, antidiabetic, antiaggregant, and anticoagulant activity. Two compounds from the family of 1,2,4-triazolo[1,5-a]pyrimidines have demonstrated anticoagulant activity at a level exceeding or at least comparable with that of dabigatran etexilate as the reference compound. 7,5-Di(2-thienyl)-4,5-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine has shown the highest ability to prolong the thrombin time, surpassing this reference drug by 2.2 times. This compound has also exhibited anticoagulant activity associated with the inhibition of thrombin (factor IIa). Moreover, the anticoagulant effect of this substance becomes enhanced under the conditions of a systemic inflammatory reaction.
Subject(s)
Anticoagulants , COVID-19 , Humans , Anticoagulants/adverse effects , Dabigatran/pharmacology , Hypoglycemic Agents , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic useABSTRACT
A fundamentally new synthetic approach to the synthesis of 2-aminopurine has been developed. It consists in the combination of the creation of a condensed polyazotic heterocyclic tetrazolopyrimidine structure, its transformation into triaminopyrimidine, and its subsequent cyclization into 2-aminopurine. The structure of the obtained compounds was established based on spectral characteristics, and the structure of the intermediate compound 5 was established directly by X-ray diffraction analysis.
ABSTRACT
The methods for modification of azoloannulated pteridines with (hetero)aromatic nucleophiles using a nucleophilic substitution of hydrogen (SNH) methodology have been developed in this work. Stable intermediate σH-adducts, as well as products of an unexpected intramolecular rearrangement of diadducts, have been isolated and characterized. The potential of the proposed approach for obtaining donor-acceptor systems, in which the pteridine fragment of the molecule acts as an acceptor, was demonstrated. The main photophysical properties of the obtained D-A compounds have been studied.
ABSTRACT
The review presents data on the synthesis as well as studies of biological activity of new derivatives of pyrimido[1,2-a]benzimidazoles published over the last decade. The bibliography of the review includes 136 sources.
ABSTRACT
The nitration of azolo[1,5-a]pyrimidin-7-amines with several nitration agents (such as acetic nitric anhydride, nitronium tetrafluoroborate, and a mixture of concentrated nitric acid and sulfuric acid) has been investigated. It has been shown that, depending on the conditions, the nitration of pyrazolopyrimidin-7-amines bearing electron-withdrawing groups in the pyrazole ring leads to nitration products in the pyrimidine and/or pyrazole ring. The nitration of triazolo[1,5-a]pyrimidin-7-amines with "nitrating mixture" has been optimized, thus allowing us to obtain a series of 6-nitro[1,2,4]triazolo[1,5-a]pyrimidin-7-amines, followed by their reduction into the corresponding [1,2,4]triazolo[1,5-a]pyrimidin-6,7-diamines (yields 86-89%). The latter have been subjected to heterocyclization by a variety of electrophilic compounds (such as CS2, glyoxal, triethyl orthoformate) with the formation of five- or six-membered annulated cycles.